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A B S T R A C T
Proteases play a vital role in lung health and are critically important to the metabolic clearance of inhaled
protein-based therapeutics after inhalation. Surprisingly little is known about lung fluid protease composition
and there is a consequent lack of biorelevant experimental models, which limits research and development in the
burgeoning field of inhaled biologics. The aim of this study was to quantify proteases in human lung fluid and to
use this data to design novel in vitro experimental models of lung lining fluid possessing biorelevant lung pro-
tease activity for use in biopharmaceutical stability studies. As a proof of concept, these novel models were used
to investigate the effect of proteolytic activity on the stability of albumin nanoparticles, a biologic nanoparticle
formulation widely investigated as a pulmonary drug delivery system. Bronchoalveolar lavage fluid was col-
lected from healthy human volunteers and proteomic analysis was used to quantify the predominant proteases.
Based on these data, four new lung protease models were constructed based on: (i) trypsin as a sole protease, (ii)
dipeptidyl peptidase IV, cathepsin D, cathepsin H, and angiotensin converting enzyme in ratio and concentration
to mimic the protease concentration in healthy lungs. Neutrophil elastase was used to model protease activity in
inflammation. Albumin nanoparticles of 100 nm diameter remained intact over 48 h in phosphate buffered
saline, but were degraded more rapidly in trypsin (50% reduction in 10 min) compared to the healthy lung
protease model (50% reduction in 150 min). The addition of neutrophil elastase to the healthy lung protease
model resulted in a similar, but more variable degradation profile. Nanoparticle degradation was associated with
concomitant appearance of small fragments and aggregates. In conclusion, we have characterised the protease
concentration in the lungs of healthy humans, designed models of lung protease activity and demonstrated their
utility in studying albumin nanoparticle degradation. These methods and models have wide application to study
the influence of proteases in lung disease, expression of proteases in respiratory cell culture models, stability of
peptide and protein-based drugs and inhaled drug delivery systems.
1. Introduction
Proteases are known to play an important role in the normal func-
tion of the healthy lungs, as well as contributing to lung pathology in
various disease states [1,2]. For inhaled biological therapies, including
proteins, peptides and antibodies, lung proteases play an important role
in their stability and pharmacokinetics [3]. For example, peptide
therapeutics have been demonstrated to undergo significant, rapid de-
gradation (t1/2 = ~6.5 min) upon incubation with lung homogenates,
which contain high pulmonary peptidase concentrations [4]. The in-
creased enzyme concentrations in the lungs associated with in-
flammation and diseases such as cystic fibrosis and chronic obstructive
pulmonary disease (COPD) has been identified as a potential barrier for
delivery of biotherapeutics by inhalation to treat respiratory diseases
[5]. As an increasing number of biological therapies and drug delivery
systems are in development for the inhaled route [6] there is clear
benefit in establishing a model of lung protease for screening bio-
pharmaceutical stability early in the medicines development process.
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A multitude of cell-based and cell-free (liquid-only) models of the
lung environment have been reported. Cell-based systems increase in
complexity from simple single cell models, e.g. 16HBE14o- and Calu-3
cell lines [7], through to multi-cell 3D co-cultures (including commer-
cial systems, e.g. MucilAir® (Alveolix) and EpiWay® (Mattek) [8–10]
and advanced engineered organ-mimicking Lung-on-a-chip systems
including models featuring “bioinspired respiration” motion [11]. Si-
milarly, a variety of cell-free fluids designed to mimic the respiratory
lining fluid have been developed for pharmaceutical development
purposes (e.g. dissolution profiles, stability and toxicity studies) which
increase in complexity from physiological-salt solutions e.g. Gamble’s
Solution [12] through to multi-phase mixtures including salts, proteins
and lipids [13]. Various studies have been reported which characterise
lung protease activity in respiratory cell cultures [14] and to investigate
the effect of lung proteases on inhaled drug integrity and transport
[15]. Baginski et al. [16] have come closest to simulating degradation
conditions within the lung, using a simple mixture of proteases to
mimic lung conditions. However, to the best of the authors’ knowledge,
no standardised, data-informed and readily prepared model of lung
protease activity has so far been reported.
Numerous proteolytic enzymes are expressed in the lungs, although
the evidence for the absolute concentrations and/or enzymatic activ-
ities of these is contradictory [17]. The aim of this study was to measure
protease concentration in human lung lavage samples and use this data
to design models of human lung protease activity, and to investigate the
stability of a model biological system, albumin nanoparticles, when
exposed to the models.
Albumin nanoparticles were selected as the test system for a proof-
of-concept investigation of particle stability in the protease models.
Albumin nanoparticles have received increasing interest as a controlled
release formulation for inhaled use. They have been demonstrated to be
well tolerated in the mouse lung, and demonstrate a long residence time
after deposition (> 48 h) [18]. This has been shown to translate to
improved treatment outcomes when used as a carrier, for example to
deliver tacrolimus for treatment of pulmonary fibrosis [19], and a
doxorubicin-TRAIL co-formulation for treatment of lung cancer [20].
An important stage in the development of this formulation for use in the
clinic will be to understand the fate of the nanoparticle carriers fol-
lowing drug release. We hypothesise that as albumin is a substrate of
many proteolytic enzymes, this biopharmaceutical formulation will be
liable to degradation in the newly developed protease model.
A quantitative study of proteases in healthy human lungs was per-
formed by the proteomic analysis of bronchoalveolar lavage fluid
(BALF) samples collected from healthy human volunteers. Proteomic
data was used to prepare four different models of lung protease for
further investigation: i) trypsin, ii) healthy lung protease, iii) elastase
and iv) inflamed lung protease. Neutrophil elastase was employed to
model the conditions of protease during lung inflammation. This po-
tent, broad-activity proteinase is well-established as a key mediator in
the lung inflammatory pathway and due to its activity against a broad
range of substrates is associated with substantial damage to the cells
and tissues of the lungs when levels become elevated [21]. In cystic
fibrosis (CF), increased neutrophil infiltration to the lungs along with
dysfunction in protease-regulatory mechanisms can lead to high local
elastase concentration [22], which in turn can result in degradation of
extracellular matrix and airway remodelling. Degradation of albumin
nanoparticles following protease exposure was monitored using dy-
namic light scattering through analysis of derived count rate (kcps) and
the particle size distribution. The effects of protease exposure were
compared to the effect of incubation in phosphate-buffered saline (PBS)
as a control.
2. Methods
2.1. Materials
Bovine serum albumin (essentially IgG-free, low endotoxin) and
dipeptidyl carboxypeptidase I/Angiotensin Converting Enzyme (ACE)
(from rabbit lung lyophilized powder; 2–6 units/mg protein; modified
Warburg-Christian) were purchased from Sigma-Aldrich (Dorset, UK).
Cathepsin D (recombinant human) was purchased from Cambridge
BioScience (Cambridge, UK). Dipeptidyl-peptidase IV (DPP4) was pur-
chased from Source BioScience (Nottingham, UK). Trypsin-Ethylene
diamine tetraacetic acid (EDTA) 0.25% w/v in Hanks Balanced Salt
Solution (HBSS) was purchased from VWR (Bedfordshire, UK).
Cathepsin H (active, human) and neutrophil elastase (recombinant
human; produced in yeast) were purchased from Generon (Slough, UK).
Phosphate buffered saline (PBS) tablets were purchased from Oxoid
(Basingstoke, UK). PBS (1x) was prepared as per the manufacturer’s
instructions using ultrapure water. Disposable, solvent resistant micro
cuvettes were purchased from Malvern Panalytical (Malvern, UK).
2.2. Proteomic analysis of human bronchoalveolar lavage samples and
design of the lung protease models
The proteomic analysis of human airway lavage fluids derived from
healthy volunteers was approved by the local ethics committee at the
University Hospital, Umea, Sweden, in accordance with the Declaration
of Helsinki. Informed written consent was obtained from all subjects
prior to inclusion into the study. Bronchoalveolar lavage (BAL) fluid
was collected from five healthy subjects (n = 27 ± 2 years, 4 females/
1 male) using established methods [23]; additional detail is provided in
the supplementary material. Following removal of mucus and cells, the
cell free lavage was concentrated using 9 K MWCO iCON Pierce con-
centrators (Thermo Scientific, UK), with the subsequent filter retentates
resuspended at equal concentrations and separated using 1D page, prior
to band excision, trypsin digestion and protein extraction. The final
peptide mixtures were analysed with an automated nanoLC MS/MS
system, followed by protein identification using Mascot (Matrix Sci-
ence, London, UK; version 1.3.0.339) and X! Tandem (The GPM,
thegpm.org; version CYCLONE (2010.12.01.1)), with protein abun-
dance calculated as the sum of the three most intense peptide precursor
ions. Full details of this proteomic pipeline are presented in the sup-
plementary material. Of the 119 identified proteins, 13 were classified
as proteases based on their gene ontologies (see Table s1, supplemen-
tary material). Of these species, 4 were confirmed as proteolytic en-
zymes with previously reported presence in the lung lining fluid (epi-
thelial lining fluid, ELF, or BAL) (Table 1). The arbitrary relative
abundance units were converted to mass values by normalisation to a
Table 1
Proteases identified in lung lining fluid and conversion to mass-based con-
centration values.
Non-Protease Relative
Abundance
Concentration (µg/
mL)
Lactoferrin 1.38E + 09 100
Proteolytic Component Relative
Abundance
Relative concentration
(µg/mL)
Dipeptidyl peptidase 4 1.64E + 07 1.19
Dipeptidyl carboxypeptidase I/
Angiotensin-converting enzyme
2.86E + 07 2.07
Pro-cathepsin H 2.79E + 07 2.02
Cathepsin D 1.10E + 09 79.9
Lower abundance proteolytic
components
7.91E + 07 5.73
SUM 90.94
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well-characterised protein concentration also identified during the
analysis. Lactoferrin was identified in BAL samples with a relative
abundance of 1.30 × 109. A literature value of lactoferrin concentra-
tion (0.1 mg/mL) was used to convert the relative abundance values of
the proteolytic enzymes to mass based concentrations [24] which were
used for the protease model construction (Eq. (1)).
⎛
⎝
⎞
⎠
= ×
Concentration of proteolytic species
x μg
mL
Relative abundance x
Relative abundance Lactoferrin
,
( )
( )
100
(1)
2.3. Preparation and characterisation of albumin nanoparticles
Albumin nanoparticles were prepared using the desolvation method
as reported previously [25]. In brief, 50 mg of bovine serum albumin
(BSA, essentially IgG-free, low endotoxin, Sigma, UK) was dissolved in
0.5 mL of 0.01 M Tris HCl (pH 8.9) and the pH adjusted to 9 with the
addition of NaOH (12.5 μL, 1 M). Ethanol (2.0 mL) was added dropwise
to the stirred protein solution at a rate of 1 mL/min. Nanoparticles were
cross-linked by addition of 8% vol/vol glutaraldehyde in water (4 μL)
followed by stirring overnight. Excess glutaraldehyde, NaOH, ethanol
and unreacted BSA were removed by four cycles of spin filtration
(100 kDa MWCO Amicon® ULTRA centrifugal spin filters, Merck-Mil-
lipore, USA) and buffer exchange with freshly prepared PBS. Con-
centration of BSA nanoparticles in the purified suspension was assessed
gravimetrically.
Particle size and polydispersity (Polydispersity Index, PdI) were
assessed using dynamic light scattering (DLS) with the Zetasizer Nano
Series ZS instrument (Malvern Panalytical, Malvern, UK). Particles were
diluted 1:10 with PBS prior to measurement. Size measurements were
performed in triplicate using a scattering angle of 173° and temperature
of 25 °C.
2.4. A dynamic light scattering method for quantification of enzyme-
mediated particle degradation
Degradation of the model biopharmaceutical system, albumin na-
noparticles, was assessed using DLS using two outputs: i) derived count
rate (kilo counts per second, kcps) and ii) particle size distribution. The
derived count rate is defined as the number of photons reaching the
detector and represents the light scattering intensity detected by the
instrument. Count rate has been demonstrated to be proportional to
nanoparticle concentration [26], and thus can be used as a tool to
monitor the proportion of intact nanoparticles remaining in suspension
following incubation in protease models. To validate the relationship
between albumin particle concentration and count rate, five calibration
suspensions were prepared at concentrations of 0.125, 0.25, 0.5, 1.0
and 2.0 mg/mL with PBS as diluent. Calibration suspensions were di-
luted 1:10 with PBS prior to measurement and analysed in triplicate at
25 °C using the Zetasizer Nano Series ZS. Five replicates of each stan-
dard curve were measured.
2.5. Particle degradation studies in four models of lung protease activity
2.5.1. Trypsin model
Based on the BAL fluid proteomics analysis, a total protease con-
centration of 0.091 mg/mL was calculated (see Section 3.1). The first
protease model prepared was a trypsin model representing the total
protease concentration in the BALF (100 µg/mL). The particle con-
centration (1.6 mg/mL) was selected to approximate the particle con-
centration in the epithelial lining fluid at the no observed adverse effect
level (NOAEL) reported in a lung biocompatibility study for this for-
mulation [18]. Albumin nanoparticles (1600 µg) were incubated with
trypsin (100 µg) and PBS (Fig. 1A) at 37 °C and samples removed at pre-
determined intervals over 48 h. Particles incubated in PBS alone at
37 °C were used as controls. Aliquots (10 μL) of the enzyme-particle
mixture were removed at 0, 0.5, 1, 2, 4, 24 and 48 h, diluted in 90 μL of
PBS and analysed immediately using the Zetasizer Nano Series ZS
(Malvern).
2.5.2. Healthy lung protease model
The second model was prepared from the four most-abundant pro-
teases identified in human BALF as a model of protease in the human
lung. For inclusion in the model, proteolytic species identified in BALF
proteomic analysis had to be i) a confirmed protease and ii) have been
previously reported to be present in respiratory tract lining fluid and/or
mucus. The four proteases chosen for the model (cathepsin D, cathepsin
H, dipeptidyl carboxypeptidase I/ angiotensin-converting enzyme
(ACE) and dipeptidyl peptidase IV) all satisfied these criteria.
Prior to the degradation study, cathepsin D was activated according
to manufacturer’s instructions. In brief, cathepsin D (125 µL) was in-
cubated with 12.5 µL of buffer (1 M NaOAc, 2 M NaCl, pH 3.8) at 37 °C,
for 30 min. The resulting activated enzyme solution was used to prepare
the healthy protease model. Albumin nanoparticles were incubated
with the pre-warmed enzymes in PBS at 37 °C at a ratio of 1600 µg
particles/ 85 µg protease (Fig. 1B). Aliquots (10 μL) were removed from
the degradation mixtures at 0, 1, 2, 3, 4, 24 and 48 h. Samples were
diluted 1:10 with PBS and immediately analysed using the Zetasizer
Nano Series ZS (Malvern) in triplicate. Particles incubated in PBS alone
(48 h, 37 °C) were also analysed at the same time points as a control.
2.5.3. Elastase and inflamed lung protease models
Neutrophil elastase was chosen to model the protease conditions in
the lung during inflammation. In this study, a previously reported lit-
erature concentration of 2.3 μM (67 μg/mL) neutrophil elastase mea-
sured in BALF samples taken from CF patients was chosen [27] for the
model. This was chosen as a conservative estimate of the concentration
present during lung inflammation, as the BALF samples were taken
from patients with mild lung disease at the time of collection. Initially,
degradation of the test albumin nanoparticle system following exposure
to NE-alone was investigated. Albumin nanoparticles were incubated
with neutrophil elastase in PBS at a ratio of 1600 μg particles/67 μg
enzyme (Fig. 1C) and degradation assessed over 24 h at 37 °C.
An inflamed lung protease model was prepared using the healthy
model with addition of neutrophil elastase. The healthy lung protease
model was prepared as described above, including pre-activation of
cathepsin D. Neutrophil elastase (100 μg/mL stock) was added to the
protease mixture to a final ratio of 1600 μg particles/67 μg enzyme
(Fig. 1D). Albumin nanoparticles were again incubated with the pre-
warmed enzymes in PBS at 37 °C, and samples removed and analysed as
per the trypsin and healthy protease model.
3. Results
3.1. BALF analysis and identification of major proteases
BALF analysis data identified 14 proteolytic species, of which the
four most abundant confirmed proteases (cathepsin D, cathepsin H,
dipeptidyl carboxypeptidase I/ angiotensin-converting enzyme (ACE),
dipeptidyl peptidase IV (DPP4)) were chosen to prepare the lung pro-
tease model. Relative abundance values as calculated from proteomic
data were converted to mass-based concentrations using Eq. (1) as
described above, resulting in concentrations of 79.9 μg/mL cathepsin D,
2.02 μg/mL pro-cathepsin H, 2.07 μg/mL ACE and 1.19 μg/mL DPP4
(Table 1). Nine further proteolytic species were identified with a
combined concentration of 5.73 μg/mL. The total concentration of
proteolytic components identified in the BALF was 90.94 μg/mL. This
data was used to inform the trypsin, healthy lung protease and lung
inflammation protease models.
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3.2. Characterisation of albumin nanoparticles as the test
biopharmaceutical system
Albumin nanoparticles to be used as the test biopharmaceutical
system for protease stability studies were manufactured in house and
characterised before use. Albumin nanoparticles were monodispersed
with a mean particle diameter of 127.6 ± 2.7 nm and narrow size
distribution (P.d.I 0.107 ± 0.021) (Fig. 2a). Particles were found to be
stable upon storage at 4 °C for up to 83 days (data not shown).
Protease-mediated particle degradation was monitored using the
derived count rate (kcps) obtained during photon correlation spectro-
scopy measurements. Count rate analysis is a simple rapid technique
allowing in situ assessment of particle degradation which has been
previously demonstrated to correlate with more traditional dissolution
and drug release studies to monitor particle breakdown [28].
To validate the relationship between count rate and albumin na-
noparticle concentration, a standard curve was prepared which de-
monstrated a linear relationship (R2 = 0.997) between albumin na-
noparticle concentration and count rate between concentrations of
0.125–2 mg/mL (Fig. 2b). This demonstrated that the analytical tech-
nique was capable of monitoring changes in albumin particle con-
centration caused by enzyme-mediated degradation in the experimental
range.
3.3. Count rate as an indicator of protease-mediated degradation
Albumin nanoparticles were employed as a test biopharmaceutical
to investigate stability to proteolytic degradation in the four protease
models: trypsin, healthy lung protease, elastase and inflamed lung
protease. Albumin nanoparticle count rate was demonstrated to
Fig. 1. Composition of the four in vitro models designed to represent the protease activity in the lungs. Healthy human lung models were based on (A) trypsin (B) a
cocktail of the four most abundant proteases recovered from human alveolar bronchial lavage fluid. Inflamed models were based on (C) neutrophil elastase, (D) the
cocktail of healthy lung proteases from (B) plus elastase from model C. The total amount of protease in models A, B, C and D was 100 µg/mL, 86 µg/mL, 67 µg/mL
and 152 µg/mL, respectively.
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undergo significant, rapid reduction following incubation in the trypsin
model (Fig. 3) with 80 ± 19% count rate drop within the first 20 min
of exposure reducing further to ~96% by 40 min. This was indicative of
a rapid, significant reduction in intact particle number following ex-
posure to the trypsin protease model.
Incubation of albumin nanoparticles in the healthy lung protease
model also resulted in a significant reduction in count rate, albeit at a
slower rate and with greater variability than the trypsin system. By 4 h,
count rate had reduced by 73.3 ± 39.4% compared with no significant
decrease following incubation in PBS alone. The count rate remained at
a similar level for the remaining 44 h of the study, indicating no further
significant change. Of interest were the large sediments detected by
visual observation at timepoints> 3 h, which were also reflected in
particle size distributions (see section 3.4). A statistically significant
decrease in the count rate was confirmed following exposure to the
healthy protease model over 48 h compared to incubation in PBS alone
(P < 0.001, 2-way ANOVA).
Neutrophil elastase degradation of albumin nanoparticles was in-
vestigated alone (elastase model) and in combination with the healthy
protease model to mimic the effect of lung inflammation (inflamed lung
Fig. 2. Characterisation of albumin nanoparticles used as test biopharmaceutical for degradation studies. Fig. 1a depicts representative particle size distribution
obtained for albumin nanoparticles at 10x dilution in phosphate-buffered saline at 25 °C. Fig. 1b represents linear relationship between derived count rate (kcps) vs
albumin nanoparticle concentration. Data represent mean ± SD (n = 5).
Fig. 3. Degradation of albumin nanoparticles following exposure to the protease models compared to phosphate buffered saline control at 37 °C for different
durations up to 48 h. The protease models were A trypsin, B) healthy lung protease model, C) elastase, and D) inflamed lung protease model. Degradation was
illustrated by the reduction in derived count rate measured using dynamic light scattering. Dotted lines (···) represent the standard deviation from the mean. Data
represent mean ± SD (N = 3–6).
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protease). This enzyme was selected as neutrophil elastase is widely
reported to be expressed at higher levels in the lung than normal during
inflammation [2]. Degradation in the elastase model demonstrated high
levels of variability in contrast to trypsin, however was still observed to
take place. When incubated with NE alone, albumin nanoparticles un-
derwent a gradual breakdown with 48.6 ± 36.8% reduction in count
rate over the first 8 h exposure, with a further significant reduction
down to 14.0 ± 13.0% of the original count rate by 24 h. Protease-
mediated count rate reduction was again significantly increased com-
pared to 24 h incubation in PBS alone (P < 0.05, 2-way ANOVA).
Interestingly, the addition of neutrophil elastase to the healthy
protease model (inflamed lung protease model) did not significantly
increase the rate of degradation despite the increased protease con-
centration in this system.
3.4. Particle size changes during protease-model mediated degradation
Changes in particle size distribution supported the findings derived
from count rate analysis and showed a clear difference in the stability of
the albumin nanoparticle test system following incubation in the four
protease models compared to PBS alone. Other than the appearance of a
small number of aggregates at 24 h onwards, no significant increase in
size or polydispersity was observed throughout the 48 h incubation in
PBS at 37 °C (Fig. 4). In contrast, significant and distinct changes were
observed following incubation in the four different protease models.
Incubation in the trypsin model resulted in the smallest change to
the particle size distribution. Three peaks were present at 2 h onwards
(10 nm, 40 nm and 400 nm) suggesting the presence of both smaller
particle fragments and larger aggregates because of protease exposure.
However, it should be noted that due to the significant drop in count
rate observed (Fig. 3), these particles represent a very small number
relative to the starting population.
Distinct differences in stability of the albumin system were observed
for the remaining three protease models. Incubation in the healthy
protease model resulted in immediate appearance of large aggregates
(1000 nm) at 0 h. By 2 h, the particle size distribution showed a highly
variable, multimodal particle population, resulting in a large standard
deviation (33%) in mean particle size (Z av at 2 h: 2462 ± 1319 nm).
Incubation of albumin nanoparticles in the elastase model resulted in
the broadening of the peak and presence of aggregates in the dis-
tribution (800 nm) by 2 h. The average particle size and standard de-
viation increased to 163 ± 65 nm, a relatively modest change com-
pared to the significant aggregation detected for the healthy protease
cocktail. By 24 h, a significant peak was also observed at 15 nm, sug-
gesting the presence of small fragments as well as particle aggregates.
Incubation in the inflamed lung protease model initially did not
induce the same extent of significant aggregation observed for the
healthy model, with a peak still visible at 120 nm. However, by 2 h only
the larger aggregates were evident in the particle size distribution
(average diameter 2680 ± 509 nm). Polydispersity (P.d.I.) increased
from 0.156 ± 0.081 at 0 h to 0.565 ± 0.191 at 2 h, again showing a
tendency to increase in polydispersity following incubation in the
protease models.
4. Discussion
The ability to predict behaviour in the lung environment is a crucial
stage in the development of any inhaled product. For biopharmaceu-
ticals, the ability to predict stability to protease in the lungs is of par-
ticular importance. Whilst in vitro models of the pulmonary environ-
ment have increased significantly in their complexity and ability to
predict performance in vivo [13], there is no generally accepted syn-
thetic model to represent protease activity in the lungs. This study es-
tablished four data-informed models of human lung protease activity,
and employed these models in a proof-of-concept study to investigate
the stability of albumin nanoparticles, an emerging biomolecular drug
carrier formulation that offers the possibility for controlled release in
the lungs [18,20]. The changes to particle size, polydispersity and
stability observed would not have been predicted following incubation
in simple buffer systems.
Proteomic analysis of BALF from healthy human volunteers was
used as the basis for the four protease models used in this study. The
analysis identified a total protease concentration of 90.9 µg/mL. The
four most abundant proteases were cathepsin D, cathepsin H, ACE and
DPPIV (Table 1), all four of which have been associated with lung tis-
sues and/or fluid. Cathepsin D, the most abundant enzyme, is an as-
partic protease which has been identified in human lung epithelial cells
and in high abundance within alveolar macrophages [29]. Cathepsin H,
a cysteine protease, has been shown to be expressed in type II alveolar
cells and alveolar macrophages [30], whilst ACE and DPPIV have both
been quantified in human epithelial lining fluid [31,32]. Very little
information has been published with respect to concentrations of pro-
teases within lung lining fluid. Juillerat-Jeanneret and colleagues [31]
reported lower enzymatic activity of DPPIV in the lung lining fluid from
healthy volunteers in terms of enzymatic activity per mL compared to
that of ACE, however the mass ratio was not reported. Rossman and
colleagues [33] reported mass-based cathepsin D concentration of
380 μg protease per 106 in alveolar macrophages.
The simplest protease model was based on trypsin at the total pro-
tease concentration in the lungs calculated from the proteomic data
(100 µg/mL). Incubation in the trypsin model resulted in rapid de-
gradation of albumin particles (50% reduction in count rate within
10 min; Fig. 2a) as indicated by drop in count rate measured from
dynamic light scattering. This concords with a report that albumin
nanoparticles (1 mg/mL particles to 50 μg/mL trypsin) were degraded
completely within 90 min, with the rate of degradation inversely pro-
portional to the glutaraldehyde crosslinking [34]. The particles used in
our study were ~15% crosslinked compared to 40% in the reported
study, which may explain the faster rate of degradation observed. The
degradation rate of albumin nanoparticles following incubation in the
healthy lung protease model was lower compared to trypsin, i.e. 50%
reduction within 150 min and 73% reduction in count rate by 4 h
(Fig. 2b). Thus, we have managed to determine the stability of albumin
nanoparticles in a biorelevant multi-protease ‘cocktail’ that combines
enzymes in amounts and proportions guided by reference to their ratio
and concentration in BAL.
Cathepsin D has been reported to degrade albumin within macro-
phages [35], and as the major component of the lung protease model it
is highly likely that it contributes significantly to nanoparticle break-
down. The optimal pH for degradation of albumin by cathepsin D has
been reported to be 3.5–4.5, but interestingly in the same study, this
optimal pH was shifted towards 5–5.4 if the protein was pre-treated
with formaldehyde [36]. As albumin nanoparticles are stabilised by
cross-linking with a related polymerizing reagent, glutaraldehyde, the
formulation of the protein into particles may change the optimal con-
ditions for degradation. Less is known about the degradation of albumin
by the other components of the model. DPPIV may be able to partially
degrade albumin, although the precise mechanism is unclear [37].
Cysteine proteinases are known to contribute to intracellular albumin
degradation [38], therefore it is reasonable to hypothesise that cathe-
psin H may also play a role in albumin nanoparticle breakdown in the
model. By contrast, albumin may inhibit the activity of ACE at its
physiological concentration (32–64 mg/mL) [39].
Two models were designed to mimic an inflammatory environment
in the lungs. Neutrophil elastase is a potent, broad-substrate enzyme
which is released during environmental or pathogen-stimulation of
neutrophils in the airway [40]. Albumin is a substrate of neutrophil
elastase, with degradation beginning within 30 min exposure [41]. Our
study demonstrates that elastase alone can breakdown albumin in na-
noparticle form. An inflamed lung protease model was prepared by
supplementing the healthy protease cocktail with neutrophil elastase.
Interestingly, the addition of NE did not result in an increase in the
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Fig. 4. Degradation, aggregation and increase in polydispersity of the test system, albumin nanoparticles, following exposure to the protease models (A: trypsin, B:
healthy lung protease, C: elastase and D: inflamed lung protease) for 24 h at 37 °C. Data represent mean ± SD (N = 3–6) and illustrate particle size distributions
determined by dynamic light scattering and include a control of albumin nanoparticles in phosphate buffered saline.
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degradation rate of albumin nanoparticles (Fig. 2). The reasons for this
are not clear, however it is reasonable to hypothesise that the failure to
increase activity may result from complex interactions between the
different proteolytic components.
To the best of the authors’ knowledge, this study represents the first
attempt to prepare a data-informed model of human lung protease
conditions and as such the model employed is a relatively simple
system. However, the model could be developed further to include the
addition of antiproteases known to be present in the lung, for example
alpha-1 anti-trypsin [42], as it would be of interest to see whether these
biomolecules affect the kinetics of protease-mediated degradation. Fu-
ture work might also explore the role that individual proteases play in
degradation, whether the proteases may interact (e.g. protease/pro-
tease degradation) and the effect of pH. Whilst it was not in the scope of
this study, it would be of significant interest to characterise the pro-
teases present within the lung lining fluid of patients with specific
disease states (e.g. cancer, asthma, respiratory infection), and to use
this data to prepare models applicable to the testing of a specific
therapeutic with its most appropriate protease environment (e.g. in-
haled antibody for asthma treatment [43] tested in asthmatic lung
protease model).
Count rate analysis using dynamic light scattering was used for
rapid, in situ monitoring of particle stability following incubation in the
protease models. Methods which employ light scattering to monitor
changes to particle stability have been reported previously. Anhalt and
colleagues [28] reported the use of in situ monitoring of nanocrystal
dissolution using count rate analysis from the Zetasizer (Malvern Pa-
nalytical). They demonstrated that the dissolution kinetics measured
using this technique correlated with conventional dissolution methods
measuring drug release. For our protease models, it was extremely
beneficial to remove the need to separate the enzyme and nanoparticles
before measurement at very early time points (e.g. in the trypsin model)
and thus in situ measurement of the count rate analysis was highly
advantageous. Another light scattering technique (turbidimetric ana-
lysis) has been employed previously to monitor the degradation of al-
bumin nanoparticles upon protease exposure [34] and reported com-
parable kinetics to our study. For other inhaled biologics, e.g. enzymes
or monoclonal antibodies, it would be of interest to include functional
assays to assess the biological activity as well as physicochemical sta-
bility over time.
Physical stability may affect the uptake, bioavailability, pro-in-
flammatory potential and even activity of a biopharmaceutical. In the
case of the albumin nanoparticle test system, both small fragments
(< 100 nm) and large aggregates (2−5 μm) were observed following
protease exposure. Whilst the presence of small fragments is intuitive
because of degradation, the precise mechanism of aggregation fol-
lowing protease exposure is not known. Lin et al. [44] have previously
reported that the degradation of albumin nanoparticles by trypsin is
likely to occur via surface erosion. As the surface charge of albumin
nanoparticles has been shown to be highly important for their physical
stability [45], we hypothesise that the changes occurring at the surface
during enzymatic metabolism may result in destabilisation and could be
the cause of the aggregation observed in this study.
The change in particle size distributions following protease ex-
posure provides interesting insight into the possible fate of these par-
ticles in the lung in vivo. We have previously reported that following
administration of In-111 labelled albumin nanoparticles to the lungs of
mice, a significant fraction of albumin-associated In-111 activity was
quantified within the lung tissue from 4 h post-deposition, along with
increased activity in BAL cells compared to deposition of albumin in its
solution form [18]. Micron-sized particles (~2–3 μm) have been de-
monstrated to undergo increased alveolar macrophage uptake com-
pared to smaller particles [46], which may suggest a possible me-
chanism for the accumulation of albumin-associated activity in BAL
cells after lung deposition. Conversely, degradation of albumin nano-
particles into smaller peptide and amino acid fragments may facilitate
their uptake into lung tissue, as absorption from the lung has been
demonstrated to be inversely proportional to molecular weight [47].
This study employed albumin nanoparticles as the first test system
to be applied to the four lung protease models. As a carrier system, the
degradation of albumin nanoparticles is primarily of interest in order to
predict drug release rates, lung retention and toxicity potential.
However, these models would also be of significant interest in future for
pharmacologically-active biomolecules, including antibody-based
therapies and therapeutic enzymes. For these biomolecules, protease-
mediated degradation could affect the function of the therapeutic and
thus render some inactive. Recent studies have suggested that en-
gineering approaches, e.g. addition of polyethylene glycol (PEG) to
biomolecules (e.g. recombinant human deoxyribonuclease I (rhDNase))
can improve their stability to proteolysis, and thus improve their ac-
tivity [48]. Changes to protein structure, including aggregation and
degradation, are known to modulate the immunogenicity of the bio-
molecules [49] and so understanding protease stability is an important
element of predicting the safety of biotherapeutics. In this context, the
development of a standardised, well-characterised model of lung pro-
tease activity is of significant value in enabling the screening of new
biomolecules for their stability, and design and testing of protective
strategies to improve resistance to protease activity before beginning in
vivo pharmacokinetic and pharmacodynamic studies. We present in this
study an important first step in the development of such a model for
widespread application in the inhaled biopharmaceutical field.
5. Conclusions
This study reports four data-informed in vitro experimental models
of human lung protease activity. We have demonstrated the significant
role that proteases can play in the stability of biotherapeutics designed
for delivery to the lungs (albumin nanoparticles) and have illustrated
the use dynamic light scattering to provide in situ monitoring of pro-
tease-mediated degradation using both the count rate and particle size
distribution outputs. As in vitro models of respiratory tissues improve in
their sophistication and ability to predict in vivo performance, this study
has highlighted a pressing need to ensure that the effects of protease are
considered in predictive models. The data presented here demonstrates
the feasibility of creating simulants that model lung protease activity
realistically and how these simulants can be employed to investigate
stability in the lung environment during inhaled biotherapeutic devel-
opment. These are key first steps in the development of fit-for-purpose,
validated and predictive models of lung protease which will be of sig-
nificant value in the pre-clinical development of biopharmaceuticals for
inhalation.
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